PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Molecular Imaging

Background:

• Noninvasive determination of integrin expression is crucial in nuclear medicine.
• Integrin αvβ3 imaging using 18F-labeled cyclic RGD peptides has advanced PET imaging.
• Recent focus includes developing tracers for integrins α5β1 and αvβ6.

Purpose of the Study:

• To review tracers evaluated in clinical trials for integrin expression imaging.
• To summarize preliminary outcomes of these clinical trials.
• To discuss recent developments in optimizing existing tracers and developing new ones.

Main Methods:

• Review of clinical trial data for RGD peptide-based radiotracers.
• Overview of advancements in 18F-labeling strategies.
• Summary of new approaches in 68Ga-complex chemistry for integrin targeting.

Main Results:

• Several RGD peptide-based tracers have been evaluated in clinical trials with preliminary outcomes summarized.
• Optimization of first-generation compounds like [18F]Galacto-RGD is ongoing.
• New radiopharmaceuticals targeting integrins α5β1 and αvβ6 are under development.

Conclusions:

• Radiotracers targeting integrins show promise for noninvasive molecular imaging in nuclear medicine.
• Continued development focuses on improving tracer efficacy and expanding targets.
• These advancements are vital for diagnosing and monitoring diseases characterized by altered integrin expression.